Gilead Updates 2026 Sales Outlook Amid Medicare Drug Price Reduction
Gilead has raised its 2026 sales forecast and announced that Medicare will reduce the price of its drug Biktarvy by 38% beginning in 2028.
Bend, OR, October 29, 2026 —
SAN FRANCISCO – Gilead Sciences has announced an upward revision to its sales forecast for the year 2026. The biopharmaceutical company did not provide specific figures for the updated forecast in the available information. The announcement comes as Medicare prepares to implement a significant price reduction for Gilead’s drug Biktarvy.
Beginning in 2028, Medicare is set to decrease the price of Biktarvy by 38%. Specific details regarding the negotiation process or the precise factors leading to this reduction were not detailed in the summary. Biktarvy is a medication used in the treatment of HIV-1 infection.
The company’s decision to raise its sales outlook suggests an expectation of continued strong performance, though the contributing factors beyond the Biktarvy price adjustment are not specified. Investors and analysts will be looking for further details on Gilead’s strategic outlook and financial projections in upcoming reports. The impending Medicare price cut for Biktarvy marks a notable change in the drug’s cost structure for the federal health insurance program, with the new pricing set to take effect in 2028.
Story summarized from the original created by By Deena Beasley on www.centraloregondaily.com, see more information here.
Media gallery
